구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | sacituzumab govitecan (Trodelvy, Sacituzumab) Merck Sharp & Dohme LLC·Muscle Invasive Bladder Urothelial… 56 trials |
|---|---|
Overview Program | Sacituzumab |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ADC |
Overview Target | Muscle Invasive Bladder Urothelial Carci |
Overview Indication | Muscle Invasive Bladder Urothelial Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Linker | cleavable peptide linker and a topoisomerase I payload with byst |
MoA Mechanism | and current clinical applications, discussing its therapeutic potential in the context of CRC |
MoA Biomarker | TROP2 glycoprotein, which is high |
PK/PD Species | Minipig, Pig |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | PK |
Toxicology Species | Minipig, Pig |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | Hepatotoxicity was predominantly found in anti-HER2 regimens |
Clinical Safety signal | Hepatotoxicity was predominantly found in anti-HER2 regimens |
Clinical Selected reported efficacy | ORR 33.3% |
Clinical Reported ORR | 33.3% |
Clinical Result source | ClinicalTrials.gov NCT03337698 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03337698 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | sacituzumab govitecan (Trodelvy, Sacituzumab) Merck Sharp & Dohme LLC·Muscle Invasive Bladder Urothelial… 56 trials |
|---|---|
Overview Program | Sacituzumab |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ADC |
Overview Target | Muscle Invasive Bladder Urothelial Carci |
Overview Indication | Muscle Invasive Bladder Urothelial Carcinoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Linker | cleavable peptide linker and a topoisomerase I payload with byst |
MoA Mechanism | and current clinical applications, discussing its therapeutic potential in the context of CRC |
MoA Biomarker | TROP2 glycoprotein, which is high |
PK/PD Species | Minipig, Pig |
PK/PD Animal (cat.) | In vitro |
PK/PD Experiment | PK |
Toxicology Species | Minipig, Pig |
Toxicology Animal (cat.) | In vitro |
Toxicology Major finding | Hepatotoxicity was predominantly found in anti-HER2 regimens |
Clinical Safety signal | Hepatotoxicity was predominantly found in anti-HER2 regimens |
Clinical Selected reported efficacy | ORR 33.3% |
Clinical Reported ORR | 33.3% |
Clinical Result source | ClinicalTrials.gov NCT03337698 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03337698 |
추천 비교
추천 비교